Trial · NCT00153101
Outcomes38
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 38
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | ONTARGET. Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction, Non-fatal Stroke and Hospitalization for Congestive Heart Failure | 56 months | FAS of the ONTARGET trial | participants | NUMBER |
| SECONDARY | ONTARGET. Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction and Non-fatal Stroke | 56 months | FAS of the ONTARGET trial | participants | NUMBER |
| SECONDARY | ONTARGET. Cardiovascular Death | 56 months | FAS of the ONTARGET trial | participants | NUMBER |
| SECONDARY | ONTARGET. Non-fatal Myocardial Infarction | 56 months | FAS of the ONTARGET trial | participants | NUMBER |
| SECONDARY | ONTARGET. Non-fatal Stroke | 56 months | FAS of the ONTARGET trial | participants | NUMBER |
| SECONDARY | ONTARGET. Hospitalization for Congestive Heart Failure | 56 months | FAS of the ONTARGET trial | participants | NUMBER |
| SECONDARY | ONTARGET. Doubling of Serum Creatinine in Diabetic Nephropathy Patients | 56 months | FAS \[DN\] of the ONTARGET trial | participants | NUMBER |
| SECONDARY | ONTARGET. Progression to End Stage Renal Disease (ESRD) in Diabetic Nephropathy Patients | 56 months | FAS \[DN\] of the ONTARGET trial | participants | NUMBER |
| SECONDARY | ONTARGET. All-cause Mortality in Diabetic Nephropathy Patients | 56 months | FAS \[DN\] of the ONTARGET trial | participants | NUMBER |
| SECONDARY | ONTARGET. Doubling of Serum Creatinine | 56 months | FAS of the ONTARGET trial | participants | NUMBER |
| SECONDARY | ONTARGET. Progression to ESRD | 56 months | FAS of the ONTARGET trial | participants | NUMBER |
| PRIMARY | ONTARGET. 3-fold Composite Endpoint of Doubling of Serum Creatinine, Progression to End Stage Renal Disease (ESRD) and All-cause Mortality in Diabetic Nephropathy Patients | 56 months | Subset of the Full Analysis Set (FAS \[DN\]) consisting of all randomised patients with diabetic nephropathy (UACR ≥300 mg/g Crea) of the ONTARGET trial. | participants | NUMBER |
| SECONDARY | ONTARGET. New Microalbuminuria | 56 months | FAS of the ONTARGET trial | participants | NUMBER |
| SECONDARY | ONTARGET. New Macroalbuminuria | 56 months | FAS of the ONTARGET trial | participants | NUMBER |
| SECONDARY | ONTARGET. Combined Endpoint of Doubling of Serum Creatinine, Progression to ESRD, New Microalbuminuria, or New Macroalbuminuria | 56 months | FAS of the ONTARGET trial | participants | NUMBER |
| SECONDARY | ONTARGET. Normalisation From Micro- or Macroalbuminuria to Normoalbuminuria | 56 months | FAS of the ONTARGET trial | participants | NUMBER |
| SECONDARY | ONTARGET. Newly Diagnosed Congestive Heart Failure | 56 months | FAS of the ONTARGET trial | participants | NUMBER |
| SECONDARY | ONTARGET. Cardiovascular Revascularization Procedure | 56 months | FAS of the ONTARGET trial | participants | NUMBER |
| SECONDARY | ONTARGET. Newly Diagnosed Diabetes | 56 months | Only patients of the ONTARGET trial treated with Telmisartan 80mg/ramipril 10mg or Telmisartan 80mg/Ramipril 10mg placebo or Ramipril 10mg/ telmisartan 80mg placebo daily for 56 months without baseline diabetes. | participants | NUMBER |
| SECONDARY | ONTARGET. Cognitive Decline | 56 months | Only patients of the ONTARGET trial treated with Telmisartan 80mg/ramipril 10mg or Telmisartan 80mg/Ramipril 10mg placebo or Ramipril 10mg/ telmisartan 80mg placebo daily for 56 months with Mini mental state evaluation (MMSE) at baseline. | participants | NUMBER |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00153101/outcomes